Loading…
Loading…
Medtronic's 49-year dividend streak sounds impressive until you meet the two medical device rivals that have been raising payouts even longer, and the differences in yield, valuation, and balance sheet strength could reshape how you think about income investing in
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
FQ4'26 noise from EP/CGM demand headwinds has contributed to Abbott's lowered FY2026 guidance and range-bound stock price action afterwards. Nutrition spin-off may unlock MedTech/Diagnostic/Pharmaceutical's growth, improve margins, and provide investors with new S&P 500-eligible stock. ABT trades at a P/E of 18.79x, below its 5Y mean/MedTech sector, offering a compelling entry point for double-digit upside potential.
Evergreen Capital Management LLC boosted its stake in shares of Abbott Laboratories (NYSE: ABT) by 40.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,737 shares of the healthcare product maker's stock after purchasing an additional 7,975 shares during
Abbott Laboratories' third-quarter results were somewhat mixed, with the company's nutrition business still dragging down sales growth. The healthcare leader announced that it would spin off its nutrition segment into a standalone company, which could help boost revenue growth.
Powered by whole-genome sequencing and MAESTRO * technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detection below one part per million under high-end inputs 1, 2, 3 The next-generation Oncodetect test builds on more than 20 years of trusted leadership in using genomic information to personalize cancer care Modeling estimates more than 3 million U.S. patients with solid tumors could potentially benefit from MRD testing † ABBOTT PARK, Ill., Oct. 26, 2026 /PRNewswire/ -- For many people with cancer, completing treatment can bring a new uncertainty: Is my cancer really gone?
Abbott Laboratories remains a Buy, driven by robust device and diagnostics growth and the strategic spin-off of its Nutrition business. Devices and diagnostics now comprise 70% of revenue, with Medical Devices up 7.8% and Diagnostics accelerating post-Exact Sciences acquisition. Spinning off Nutrition is expected to boost ABT's growth rate by 50–100 bps, expand gross margin by 200 bps, and improve operating margin by 100 bps.